How do you know if you need HRT? - Reddit

Are symptoms enough to know if you need HRT?

The classic symptoms of hormone deficiency are well-documented. For women approaching or after menopause: hot flashes, night sweats, vaginal dryness and atrophy, mood instability, sleep disruption, brain fog, and a decline in libido. These symptoms can significantly impact quality of life, and they are the most common reason women ask whether they need HRT.

For men, the symptom picture of low testosterone (hypogonadism) is somewhat different: persistent fatigue unrelated to sleep, reduced motivation and drive, mood changes or irritability, loss of muscle mass and strength despite consistent effort, increased body fat (particularly visceral), poor recovery from exercise, and reduced libido.

The challenge with all of these symptoms is that they overlap substantially with many other conditions: thyroid dysfunction, depression, sleep apnea, nutritional deficiencies, chronic stress, and normal life variation. This is why symptoms are the clinical starting point, not the basis for a prescription on their own.

What labs confirm HRT eligibility?

Lab confirmation is what separates a symptom-driven conversation from a clinical decision. Here is what clinicians typically look for.

For women

The primary hormonal markers evaluated before prescribing HRT for women include:

• FSH and LH: Follicle-stimulating hormone and luteinizing hormone rise significantly as ovarian function declines. An FSH above 40 mIU/mL in the context of symptoms is a strong indicator of menopause.
• Estradiol (E2): Falling estradiol levels confirm estrogen deficiency. Timing matters for women still cycling — labs drawn at the wrong phase of the cycle may misrepresent estrogen status.
• Progesterone: Assessed to understand the estrogen-progesterone balance, particularly relevant for women with an intact uterus (where progestogen is required alongside estrogen therapy).
• TSH: Thyroid dysfunction overlaps substantially with menopausal symptoms. Ruling it out before attributing symptoms to estrogen deficiency is standard practice.

For men

The Endocrine Society guidelines define male hypogonadism clinically as consistently low morning testosterone (below 300 ng/dL on two separate measurements) combined with symptoms. Labs typically include:

• Total testosterone (morning draw): The primary screening value. Must be drawn in the morning when levels peak. A single low value should be confirmed with a repeat draw.
• Free testosterone: Total testosterone can be misleading if SHBG is elevated (e.g., in older men, hyperthyroid states). Free T gives a clearer picture of bioavailable hormone.
• LH and FSH: Help distinguish primary hypogonadism (testicular failure) from secondary (pituitary/hypothalamic), which has different treatment implications.
• Hematocrit/CBC: Baseline needed because testosterone therapy can increase red blood cell production (polycythemia), which requires monitoring.
• PSA: For men over 40, a prostate-specific antigen baseline is standard before initiating testosterone therapy.

Who is HRT not appropriate for?

HRT is not appropriate for everyone, and a responsible clinician will review your history carefully before prescribing. Known contraindications for women include:

• Personal history of hormone-sensitive cancers (breast, endometrial, ovarian)
• Unexplained or undiagnosed vaginal bleeding
• Active venous thromboembolism (VTE) or high clotting risk
• Active liver disease
• Pregnancy or suspected pregnancy

For men seeking testosterone therapy, contraindications include:

• History of prostate cancer or breast cancer
• Severe untreated sleep apnea
• Uncontrolled polycythemia
• Desire to preserve fertility (exogenous testosterone suppresses spermatogenesis)
• Hematocrit above 54% at baseline

These are the clinician’s domain to evaluate — not a self-diagnosis exercise. If you have any of these risk factors, that context shapes what therapy is appropriate, not necessarily rules it out entirely.

When should women start HRT? The timing question

Current evidence favors initiating hormone therapy earlier in the menopausal transition rather than waiting until years after the final menstrual period. This “timing hypothesis” is supported by observational and mechanistic data suggesting that the cardiovascular and bone-protective effects of estrogen therapy are most pronounced when initiated during the early perimenopause or within the first decade of menopause, rather than in older postmenopausal women.

The Women’s Health Initiative (WHI) study — which generated significant anxiety about HRT in the early 2000s — enrolled older postmenopausal women, and subsequent analyses suggested the elevated cardiovascular risks observed in that cohort were partly explained by timing. The Menopause Society’s 2022 position statement is notably more favorable toward HRT initiation in appropriate candidates than earlier guidance.

How does the HRT evaluation process work in practice?

A clinician-supervised HRT evaluation typically follows this sequence:

1. Intake assessment: You complete a structured intake covering your symptoms, health history, family history, current medications, and goals.
2. Lab draw: A clinician orders or reviews your hormone panel and relevant health markers.
3. Clinical review: A licensed clinician reviews your labs in context of your symptoms and history, identifies whether hormone deficiency is confirmed, and assesses contraindications.
4. Protocol and prescription: If appropriate, the clinician prescribes the formulation, dose, and route of administration suited to your clinical picture.
5. Follow-up monitoring: Labs and clinician check-ins at regular intervals to assess response, adjust dosing, and monitor safety markers.

Frequently asked questions